Welcome to our dedicated page for Akero Therapeutics SEC filings (Ticker: AKRO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing efruxifermin (EFX) for metabolic dysfunction-associated steatohepatitis (MASH) and related metabolic liver diseases. These regulatory documents offer detailed insight into Akero’s clinical programs, financial position, risk factors and corporate transactions.
Through its annual reports on Form 10-K and quarterly reports on Form 10-Q, Akero describes its business focus on serious metabolic diseases, outlines the design and objectives of the Phase 3 SYNCHRONY program, and discusses prior Phase 2b HARMONY and SYMMETRY results. Management’s discussion and analysis sections explain research and development spending, including costs associated with large global trials and manufacturing of clinical supplies for potential marketing applications.
Current reports on Form 8-K highlight material events. For example, Akero has filed an 8-K describing its Agreement and Plan of Merger with Novo Nordisk A/S and a wholly owned subsidiary of Novo Nordisk, under which Akero is expected to become a wholly owned subsidiary following stockholder approval and satisfaction of closing conditions. Another 8-K details the voluntary prepayment and termination of a prior loan agreement, providing context on changes in the company’s capital structure and debt obligations. Additional 8-K filings furnish quarterly earnings press releases and other significant updates.
Investors researching insider activity can review Forms 4 referenced in Akero’s proxy materials, which report changes in beneficial ownership by directors and executive officers. When available, proxy statements and related solicitation materials explain executive compensation, governance matters and, in connection with the proposed merger, information relevant to the stockholder vote. Stock Titan’s platform surfaces these filings as they are posted to EDGAR and adds AI-powered summaries to help readers interpret lengthy documents such as 10-Ks, 10-Qs, 8-Ks and proxy statements without having to parse every page manually.
Akero Therapeutics (AKRO) director Graham G. Walmsley reported multiple option exercises and acquisitions on
The transactions were disclosed on a single Form 4 filed by one reporting person; the filer disclaims beneficial ownership except for pecuniary interest. The signature block shows the form was signed by an attorney‑in‑fact on
Akero Therapeutics (AKRO) Form 4 shows Chief Scientific Officer Timothy Rolph used a Rule 10b5-1 plan to exercise 12,500 vested stock options at an exercise price of
Andrew Cheng, who serves as President and CEO and a director of Akero Therapeutics, Inc. (AKRO), reported a change in beneficial ownership dated 10/08/2025. The filing shows an acquisition of 52,212 shares/options at a price of $0.615 per share, and after the reported transaction Mr. Cheng beneficially owns 526,114 shares. The document also discloses a derivative entry for 52,212 stock options with the same exercise price; the filer notes these options are vested and currently exercisable. The Form is signed by an attorney-in-fact on 10/09/2025.
Akero Therapeutics agreed to be acquired by Novo Nordisk through a merger that will make Akero a wholly owned subsidiary of Novo Nordisk. The transaction includes cash consideration and a contingent value right (CVR) structure that awards one CVR per share and ties payments to specified regulatory and commercial milestones; in-the-money stock options will be cashed out plus converted into CVRs on a per-share basis. The merger is subject to customary closing conditions including antitrust and foreign investment clearances and approval by holders of a majority of Akero's common stock. Akero will file a proxy statement with additional details and warns that CVRs may yield no payment if milestones are not met and that regulatory approvals, competing offers, or other closing conditions could prevent or delay completion.
Deep Track entities and individual David Kroin reported ownership of 4,400,000 shares of Akero Therapeutics common stock, representing
The statement certifies the position was not acquired to change or influence control of the issuer and includes a joint filing agreement assigning responsibility for future amendments. The ownership percentage and shared control are material to investors because the stake exceeds the 5% reporting threshold and is publicly disclosed under SEC rules.
Akero Therapeutics, Inc. (AKRO) Form 144 shows an insider sale notice for 56,369 shares of common stock to be sold through J.P. Morgan Securities LLC on
Jonathan Young, Chief Operating Officer of Akero Therapeutics, Inc. (AKRO), reported multiple transactions on 10/01/2025 under a Rule 10b5-1 plan. He acquired 12,500 stock options at an exercise price of $21.10 and exercised options that resulted in ownership of 82,482 common shares in total. On the same date he sold 12,500 common shares via a market sale at a weighted-average price of $21.10 (option acquisition) and separately sold 8,299 shares at a weighted-average price of $47.644 and 4,201 shares at a weighted-average price of $47.984. Following the reported transactions, he directly beneficially owned 196,898 shares. He also holds indirect interests of 20,000 shares each through three irrevocable trusts for his children, which he disclaims as beneficial ownership.
Akero Therapeutics, Inc. voluntarily repaid in full its outstanding debt under a term loan facility with Hercules Capital. On September 23, 2025, the company paid an aggregate $37.6 million, covering all outstanding principal, accrued and unpaid interest, fees, costs and expenses under its Loan and Security Agreement.
Following receipt of this payoff amount, all obligations, covenants, debts and liabilities under the loan were satisfied and discharged, and the Loan Agreement and related documents were terminated, other than the existing warrants. The facility had allowed borrowings of up to $150 million, of which Akero had drawn $35 million at a variable interest rate with a scheduled maturity in March 2027.
Akero Therapeutics insider transaction summary: Chief Scientific Officer Timothy Rolph executed multiple transactions on 09/08/2025 under a Rule 10b5-1 trading plan. The Form 4 reports sales totaling 12,500 common shares (12,466 shares at a weighted-average price of $44.169 and 34 shares at $44.875) and three option-related acquisitions recorded as M(1) exchanges: 7,044 option rights with $21.09 strike, 5,161 option rights with $6.364 strike, and 295 option rights with $28.35 strike. Following the transactions, Rolph beneficially owned 167,124 common shares (direct). The filing notes the options are vested and exercisable and that the trades were effected pursuant to a 10b5-1 plan dated August 12, 2024.
Akero Therapeutics (AKRO) Form 144 filing reports a proposed sale of Common Stock by an insider. The notice lists a broker, J.P. Morgan Securities, and an approximate aggregate market value of the proposed sale at $4,015,800 for 90,000 shares, with an approximate sale date of 09/10/2025 on NASDAQ. The filing details the insider's acquisition history: 478 shares from an ESPP on 06/28/2024, 14,581 shares from RSU vesting on 03/09/2023, and 74,941 shares from a stock option exercise on 09/10/2025. It also discloses recent dispositions: 30,000 shares sold on 07/10/2025 for $1,534,895 and 30,000 shares sold on 08/11/2025 for $1,457,589. The filer represents no undisclosed material adverse information.
FAQ
What is the current stock price of Akero Therapeutics (AKRO)?
What is the market cap of Akero Therapeutics (AKRO)?
